Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 6 mechanisms across 8 industry trials with a known mechanism of action.

See full pipeline →

Programmed Death Receptor-1 Blocking Antibody

3 trials 2 active 1 sponsor

Tissue Factor/Tubulin

1 trials 1 active 1 sponsor

Programmed Death Ligand-1 Blocker

1 trials 1 sponsor

Vascular Endothelial Growth Factor Inhibitor

1 trials 1 sponsor

Nuclear Export Inhibitor

1 trials 1 sponsor

Kinase Inhibitor

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

204 industry-sponsored trials across 136 sponsors

View full landscape →

Showing 4 of 4 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Pfizer	TIVDAK	Tissue Factor/Tubulin	RECRUITING	2028-12-13	NCT06952660
Xiamen Innovax Biotech Co., Ltd	Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®	—	COMPLETED	2020-08-01	NCT05426148
Merck	V501	—	COMPLETED	2016-08-27	NCT01544478
GSK	Cervarix	—	TERMINATED	2012-01-16	NCT00730847

Showing 40 of 40 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Bio-Thera Solutions	Recombinant humanized anti-PD-1 monoclonal antibody injection	—	RECRUITING	2026-09	NCT06123884
Lee's Pharmaceutical Limited	Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab	—	RECRUITING	2027-09-01	NCT06459687
Shanghai Bovax Biotechnology Co., Ltd.	9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)	—	RECRUITING	2027-09-15	NCT04422366
AstraZeneca	Volrustomig	—	RECRUITING	2027-11-26	NCT06079671
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-A2102 for Injection	—	RECRUITING	2027-12	NCT07418749
Mabwell (Shanghai) Bioscience Co., Ltd.	9MW2821	—	RECRUITING	2027-12-09	NCT06692166
Shanghai Shengdi Pharmaceutical Co., Ltd	SHR-1316 Injection	—	RECRUITING	2028-04	NCT07168200
Merck	Sacituzumab Tirumotecan	—	RECRUITING	2028-06-15	NCT06459180
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	RECRUITING	2031-10-29	NCT07216703
Shanghai Bovax Biotechnology Co., Ltd.	2-doses Group among 9-14 years	—	RECRUITING	2023-11-22	NCT05027776
Shanghai Bovax Biotechnology Co., Ltd.	9-valent HPV vaccine	—	RECRUITING	2023-01-13	NCT04895020
Akeso	AK104	—	ACTIVE NOT RECRUITING	2026-05	NCT05235516
Akeso	AK104	—	ACTIVE NOT RECRUITING	2025-12-30	NCT04982237
Jiangsu HengRui Medicine Co., Ltd.	camrelizumab； famitinib malate	—	ACTIVE NOT RECRUITING	2025-06-10	NCT04906993
CSPC Megalith Biopharmaceutical Co.,Ltd.	SYS6002	—	NOT YET RECRUITING	2028-01-01	NCT07230626
L & L Bio Co., Ltd., Ningbo, China	LB1410	—	NOT YET RECRUITING	2028-12	NCT07177716
Shanghai Jiatan Pharmatech Co., Ltd	WX390 1.1mg + Toripalimab 240mg	—	NOT YET RECRUITING	2029-09-30	NCT07392060
Guangzhou Gloria Biosciences Co., Ltd.	GLS-010	—	NOT YET RECRUITING	2025-05-01	NCT05798819
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	SG001 injection	—	NOT YET RECRUITING	2024-07-31	NCT05715840
Merck	V501	—	COMPLETED	2023-10-30	NCT03493542
Seagen, a wholly owned subsidiary of Pfizer	tisotumab vedotin	—	COMPLETED	2023-07-24	NCT04697628
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2022-10-03	NCT03635567
Shanghai Bovax Biotechnology Co., Ltd.	Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)	—	COMPLETED	2022-06-17	NCT05372016
AstraZeneca	Durvalumab	Programmed Death Ligand-1 Blocker [EPC]	COMPLETED	2022-01-20	NCT03830866
Shanghai Bovax Biotechnology Co., Ltd.	4-valent HPV Vaccine	—	COMPLETED	2021-09-06	NCT04425291
Zeria Pharmaceutical	Z-100	—	COMPLETED	2021-07-20	NCT03476018
Zeria Pharmaceutical	Z-100	—	COMPLETED	2021-06-29	NCT02247232
Regeneron	Cemiplimab	—	COMPLETED	2021-03-15	NCT03257267
El Kendi Pharmaceuticals Manufacturing Company	Nimotuzumab ( h-R3)	—	COMPLETED	2020-03	NCT03413579
Merck	V503	—	COMPLETED	2018-11-19	NCT03158220
Taiho Pharmaceutical Co., Ltd.	S-1 + Cisplatin (arm A)	—	COMPLETED	2015-12	NCT00770874
Merck	V503	—	COMPLETED	2011-06-10	NCT01047345
Merck	V503	—	COMPLETED	2011-04-30	NCT00943722
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102	—	TERMINATED	2024-08-12	NCT05179239
Shanghai Bovax Biotechnology Co., Ltd.	Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)	—	TERMINATED	2023-03-23	NCT05584332
Qilu Pharmaceutical Co., Ltd.	QL1604	—	TERMINATED	2022-09-30	NCT04864782
Advaxis, Inc.	ADXS11-001	—	TERMINATED	2019-07-31	NCT02853604
Shandong New Time Pharmaceutical Co., LTD	Rulonilimab	—	ENROLLING BY INVITATION	2028-09	NCT06755515
Shanghai Henlius Biotech	HLX10	—	WITHDRAWN	2024-02-15	NCT04806945
Agenus Inc.	Balstilimab (BAL)	—	WITHDRAWN	2021-10-22	NCT04943627

Showing 90 of 90 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Theravectys S.A.	Two IM injections Lenti-HPV-07	—	RECRUITING	2026-06	NCT06319963
Medicenna Therapeutics, Inc.	MDNA11	—	RECRUITING	2026-06-30	NCT05086692
MediLink Therapeutics (Suzhou) Co., Ltd.	YL202	—	RECRUITING	2026-08-31	NCT07202364
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-A1811	—	RECRUITING	2026-10	NCT06859775
Precigen, Inc	PRGN-2009 plus Pembrolizumab	—	RECRUITING	2026-11-11	NCT06157151
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1	—	RECRUITING	2026-12	NCT05990803
Shanghai Henlius Biotech	HLX43	—	RECRUITING	2026-12-31	NCT06769152
Evopoint Biosciences Inc.	XNW28012	—	RECRUITING	2026-12-31	NCT06799637
Neonc Technologies, Inc.	NEO212 Oral Capsule	—	RECRUITING	2027-02-28	NCT06047379
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1	—	RECRUITING	2027-05	NCT07054567
RemeGen Co., Ltd.	Disitamab Vedotin	—	RECRUITING	2027-06-30	NCT06155396
Suzhou Zelgen Biopharmaceuticals Co.,Ltd	ZG005	—	RECRUITING	2027-08	NCT07080216
Daiichi Sankyo	HER3-DXd	—	RECRUITING	2027-09-01	NCT06172478
Radiopharm Theranostics, Ltd	177Lu-BetaBart	—	RECRUITING	2027-12	NCT07189871
Precision Biologics, Inc	NEO-201 in combination with pembrolizumab	—	RECRUITING	2028-01-15	NCT03476681
GI Innovation, Inc.	GI-101	—	RECRUITING	2028-06-30	NCT04977453
Bristol-Myers Squibb	BMS-986340	—	RECRUITING	2028-07-07	NCT04895709
ModeX Therapeutics, An OPKO Health Company	MDX2001	—	RECRUITING	2028-08	NCT06239194
Tanabe Pharma America, Inc.	MT-4561	—	RECRUITING	2028-08	NCT06943521
Evopoint Biosciences Inc.	XNW5004	—	RECRUITING	2028-08	NCT06022757
AstraZeneca	Volrustomig	—	RECRUITING	2028-11-30	NCT06535607
Terremoto Biosciences Inc.	TER-2013	—	RECRUITING	2028-12-30	NCT07109726
Suzhou Zelgen Biopharmaceuticals Co.,Ltd	ZG005 Powder for Injection	—	RECRUITING	2026-05	NCT06241235
Jiangsu HengRui Medicine Co., Ltd.	SHR-A1811 Injection	—	RECRUITING	2026-02	NCT07051486
Innolake Biopharm	ILB-2109	—	RECRUITING	2026-01-25	NCT05955105
GeneMedicine Co., Ltd.	GM103 (Part A)	—	RECRUITING	2025-05-30	NCT06265025
OncoC4, Inc.	ONC-392	—	ACTIVE NOT RECRUITING	2026-06-30	NCT04140526
Klus Pharma Inc.	SKB264	—	ACTIVE NOT RECRUITING	2026-12-31	NCT04152499
Merck	pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	ACTIVE NOT RECRUITING	2027-05-04	NCT02628067
AstraZeneca	AZD5305	—	ACTIVE NOT RECRUITING	2027-05-28	NCT04644068
Ascendis Pharma Oncology Division A/S	TransCon IL-2 β/γ	—	ACTIVE NOT RECRUITING	2027-08	NCT05081609
Qurient Co., Ltd.	Q702	—	ACTIVE NOT RECRUITING	2027-12-30	NCT05438420
AstraZeneca	Volrustomig	—	ACTIVE NOT RECRUITING	2028-03-13	NCT06943833
ImmunityBio, Inc.	N-803 + Pembrolizumab	—	ACTIVE NOT RECRUITING	2029-08-31	NCT03228667
Xencor, Inc.	vudalimab	—	ACTIVE NOT RECRUITING	2025-10-15	NCT05032040
NextCure, Inc.	NC410	—	ACTIVE NOT RECRUITING	2025-07	NCT05572684
NGM Biopharmaceuticals, Inc	NGM707	—	ACTIVE NOT RECRUITING	2025-02	NCT04913337
Transgene	TG4001	—	ACTIVE NOT RECRUITING	2024-09-18	NCT03260023
Tasly Biopharmaceuticals Co., Ltd.	B1962	—	NOT YET RECRUITING	2026-08	NCT06724263
Jiangsu Alphamab Biopharmaceuticals Co., Ltd	JSKN033	—	NOT YET RECRUITING	2027-10	NCT07497074
MGB Pharma	The monoterpenoid zinc tetra-ascorbo-camphorate ("C14")	—	NOT YET RECRUITING	2025-03-15	NCT06672653
CRISPR Therapeutics AG	CTX131	—	COMPLETED	2025-09-18	NCT05795595
Jiangsu HengRui Medicine Co., Ltd.	SHR-1210	—	COMPLETED	2025-07-07	NCT04680988
Akeso	AK104	—	COMPLETED	2024-09-27	NCT05227651
Laekna Limited	Afuresertib	—	COMPLETED	2024-06-25	NCT05383482
Akeso	AK104	—	COMPLETED	2024-02-28	NCT04868708
Shandong New Time Pharmaceutical Co., LTD	Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection	—	COMPLETED	2023-12-05	NCT06226350
Nykode Therapeutics ASA	VB10.16	—	COMPLETED	2023-11-24	NCT04405349
Innovent Biologics (Suzhou) Co. Ltd.	IBI310	—	COMPLETED	2023-11-20	NCT04590599
Regeneron	Cemiplimab	—	COMPLETED	2023-05-22	NCT04646005
Akeso	AK104	—	COMPLETED	2022-12-22	NCT04380805
Agenus Inc.	AGEN1884 + AGEN2034	—	COMPLETED	2022-07-15	NCT03495882
BeiGene	Tislelizumab	—	COMPLETED	2022-06-16	NCT04693234
Agenus Inc.	AGEN2034	—	COMPLETED	2022-06-15	NCT03104699
Genexine, Inc.	GX-188E	—	COMPLETED	2022-04-29	NCT03444376
National Vaccine and Serum Institute, China	Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)	—	COMPLETED	2022-03-01	NCT04436133
Klus Pharma Inc.	A166	—	COMPLETED	2022-01-12	NCT03602079
Roche	Tiragolumab	—	COMPLETED	2021-12-08	NCT04300647
Genmab	Enapotamab vedotin (HuMax-AXL-ADC)	—	COMPLETED	2021-11-12	NCT02988817
Seagen Inc.	tisotumab vedotin	—	COMPLETED	2020-02-06	NCT03438396
SK Bioscience Co., Ltd.	NBP615	—	COMPLETED	2019-12-30	NCT04453241
Gradalis, Inc.	Vigil	—	COMPLETED	2019-05-22	NCT03073525
Gilead	Sacituzumab Govitecan-hziy (SG)	—	COMPLETED	2019-03-01	NCT01631552
Catalysis SL	—	—	COMPLETED	2019-02-01	NCT03540407
Roche	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	COMPLETED	2018-12-31	NCT02467907
ISA Pharmaceuticals	ISA101/ISA101b	—	COMPLETED	2018-08	NCT02128126
Inovio Pharmaceuticals	INO-3112	—	COMPLETED	2017-09-07	NCT02172911
Karyopharm Therapeutics Inc	Selinexor	Nuclear Export Inhibitor [EPC]	COMPLETED	2017-01-24	NCT02025985
Siemens Molecular Imaging	[F 18]HX4	—	COMPLETED	2011-05	NCT01075399
Seagen, a wholly owned subsidiary of Pfizer	Tisotumab Vedotin	—	TERMINATED	2026-03-19	NCT03786081
TCRCure Biopharma Ltd.	TC-E202 cells	—	TERMINATED	2026-01-15	NCT05357027
Ocellaris Pharma, Inc.	OC-001	—	TERMINATED	2025-11-07	NCT04260802
Iovance Biotherapeutics, Inc.	LN-145	—	TERMINATED	2025-08-22	NCT03108495
Telix Pharmaceuticals (Innovations) Pty Ltd	—	—	TERMINATED	2025-05-09	NCT05563272
Agenus Inc.	AGEN2034	—	TERMINATED	2025-03-26	NCT03894215
Aminex Therapeutics, Inc.	AMXT1501	—	TERMINATED	2024-12-12	NCT05500508
Kymab Limited	Alomfilimab	—	TERMINATED	2024-10-03	NCT03829501
Rain Oncology Inc	RAIN-32	—	TERMINATED	2023-10-15	NCT05012397
Roche	simlukafusp alfa	—	TERMINATED	2021-12-30	NCT03386721
Advaxis, Inc.	ADXS11-001	—	TERMINATED	2019-07-09	NCT02291055
Advenchen Laboratories, LLC	AL3818	—	TERMINATED	2017-02-14	NCT02558348
BIND Therapeutics	BIND-014 (docetaxel nanoparticles for injectable suspension)	—	TERMINATED	2016-10	NCT02479178
Merck	Sotatercept 15 mg	—	TERMINATED	2012-09-21	NCT01284348
PharmaMar	Zalypsis ( PM00104)	—	TERMINATED	2011-09	NCT00900562
Merck	adavosertib	—	TERMINATED	2011-06-13	NCT01076400
Nykode Therapeutics ASA	VB10.16	—	WITHDRAWN	2027-05	NCT06099418
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	TQB2868 injection	—	WITHDRAWN	2025-02	NCT05998941
Agenus Inc.	Balstilimab	—	WITHDRAWN	2024-12-30	NCT05033132
NKGen Biotech, Inc.	SNK01	—	WITHDRAWN	2022-08	NCT04464967
Novartis	BKM120	—	WITHDRAWN	2017-09	NCT01613677

Showing 70 of 70 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Nurix Therapeutics, Inc.	NX-1607	—	RECRUITING	2026-08-31	NCT05107674
Therorna	therapeutic tumor vaccine	—	RECRUITING	2026-09-20	NCT07081984
SystImmune Inc.	BL-B01D1	—	RECRUITING	2026-12-31	NCT05983432
Orano Med LLC	²¹²Pb-DOTAM-GRPR1	—	RECRUITING	2027-01	NCT05283330
Solve Therapeutics	SLV-154	—	RECRUITING	2027-01	NCT06771219
Kortuc, Inc.	KRC-01	—	RECRUITING	2027-01-30	NCT05570422
ViroMissile, Inc.	IDOV-Immune (oncolytic vaccinia virus)	—	RECRUITING	2027-01-31	NCT06910657
Eli Lilly	LY4052031	—	RECRUITING	2027-05	NCT06465069
Normunity AccelCo, Inc.	NRM-823	—	RECRUITING	2027-05-30	NCT07182149
Dren Bio	DR-0202	—	RECRUITING	2027-07	NCT06999187
KaliVir Immunotherapeutics	VET3-TGI	—	RECRUITING	2027-09-30	NCT06444815
Sutro Biopharma, Inc.	STRO-004	—	RECRUITING	2027-12	NCT07227168
HRYZ Biotech Co.	HRYZ-T101 Injection	—	RECRUITING	2027-12	NCT05952947
Chongqing Precision Biotech Co., Ltd	CD70-targeted CAR-T cells	—	RECRUITING	2028-03-31	NCT07181720
Regor Pharmaceuticals Inc.	RGT-490	—	RECRUITING	2028-04	NCT07524322
MacroGenics	MGC026 Dose Escalation	—	RECRUITING	2028-05	NCT06242470
Roche	Enzelkitug	—	RECRUITING	2028-07-31	NCT05581004
SystImmune Inc.	BL-M07D1	—	RECRUITING	2028-12-15	NCT06293898
Radiopharm Theranostics, Ltd	RAD301 ([68Ga]-RAD301)	—	RECRUITING	2026-05	NCT05799274
BlueSky Immunotherapies GmbH	FluBHPVE6E7	—	RECRUITING	2025-09	NCT05829629
Suzhou BlueHorse Therapeutics Co., Ltd.	Autologous tumor infiltrating lymphocytes (TILs)	—	RECRUITING	2024-05-30	NCT05366478
OncoC4, Inc.	AI-061	—	ACTIVE NOT RECRUITING	2026-07-31	NCT05858736
HiFiBiO Therapeutics	HFB200301	—	ACTIVE NOT RECRUITING	2026-12	NCT05238883
TScan Therapeutics, Inc.	TSC-204-A0201	—	ACTIVE NOT RECRUITING	2026-12-30	NCT05973487
AbbVie	IMGN151	—	ACTIVE NOT RECRUITING	2027-02	NCT05527184
Eli Lilly	LY4101174	—	ACTIVE NOT RECRUITING	2027-03	NCT06238479
Atavistik Bio, Inc	ATV-1601	—	ACTIVE NOT RECRUITING	2028-08-31	NCT07038369
Arcus Biosciences, Inc.	AB598	—	ACTIVE NOT RECRUITING	2026-03	NCT05891171
Adcentrx Therapeutics	ADRX-0706	—	ACTIVE NOT RECRUITING	2025-09	NCT06036121
NGM Biopharmaceuticals, Inc	NGM831	—	ACTIVE NOT RECRUITING	2025-07	NCT05215574
Adlai Nortye Biopharma Co., Ltd.	AN0025	—	ACTIVE NOT RECRUITING	2024-05-31	NCT04432857
Corregene Biotechnology Co., Ltd	CRTE7A2-01 TCR-T cell therapy	—	NOT YET RECRUITING	2027-12-31	NCT06358053
Arcus Biosciences, Inc.	AB308	—	COMPLETED	2025-08-25	NCT04772989
Risen (Suzhou) Pharma Tech Co., Ltd.	RP903	—	COMPLETED	2025-05-30	NCT06846099
Exelixis	XB002	—	COMPLETED	2025-03-10	NCT04925284
AstraZeneca	AZD8701	—	COMPLETED	2024-10-07	NCT04504669
Incyte Corporation	INCB099280	—	COMPLETED	2024-08-29	NCT04242199
Xencor, Inc.	XmAb®23104	—	COMPLETED	2024-02-15	NCT03752398
Xencor, Inc.	XmAb®22841	—	COMPLETED	2023-02-16	NCT03849469
MacroGenics	tebotelimab 1 mg	—	COMPLETED	2023-02-08	NCT03219268
Prelude Therapeutics	PRT1419	—	COMPLETED	2023-02-06	NCT04837677
Corvus Pharmaceuticals, Inc.	CPI-006	—	COMPLETED	2022-12-28	NCT03454451
Fate Therapeutics	FT500	—	COMPLETED	2022-11-15	NCT03841110
Quadriga Biosciences, Inc.	QBS10072S	—	COMPLETED	2022-09-21	NCT04430842
EMD Serono Research & Development Institute, Inc.	M7824	—	COMPLETED	2022-06-15	NCT04551950
Xencor, Inc.	XmAb20717	—	COMPLETED	2022-06-01	NCT03517488
Andes Biotechnologies	Andes-1537 for Injection	—	COMPLETED	2022-02-17	NCT03985072
National Vaccine and Serum Institute, China	11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)	—	COMPLETED	2021-10-13	NCT04083196
Incyte Corporation	INCAGN02390	—	COMPLETED	2021-08-18	NCT03652077
Incyte Biosciences International Sàrl	INCAGN02385	—	COMPLETED	2020-10-07	NCT03538028
Antiva Biosciences	Topical ABI-1968	—	COMPLETED	2020-05-26	NCT03697226
Shanghai Bovax Biotechnology Co., Ltd.	9-valent HPV Recombinant Vaccine	—	COMPLETED	2019-08-20	NCT03676101
AstraZeneca	AZD5363	—	COMPLETED	2019-04-26	NCT01226316
Antiva Biosciences	ABI-1968	—	COMPLETED	2018-10-30	NCT03239223
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Bevacizumab injection	—	COMPLETED	2017-08-18	NCT05476341
Advaxis, Inc.	Axalimogene filolisbac	—	COMPLETED	2017-03-08	NCT02164461
Novartis	everolimus	Kinase Inhibitor [EPC]	COMPLETED	2014-04	NCT01217177
Fusion Pharmaceuticals Inc.	[111In]-FPI-1547 Injection	—	TERMINATED	2025-12-03	NCT03746431
Pheon Therapeutics	PHN-010	—	TERMINATED	2025-09-11	NCT06457997
Molecular Templates, Inc.	MT-8421	—	TERMINATED	2024-10-31	NCT06034860
SOTIO Biotech AG	Nanrilkefusp alfa	—	TERMINATED	2024-08-31	NCT04234113
Incyte Corporation	INCB099318	—	TERMINATED	2024-08-16	NCT04272034
Seagen Inc.	SEA-TGT	—	TERMINATED	2023-12-01	NCT04254107
Nurix Therapeutics, Inc.	Drug Product De-TIL-0255	—	TERMINATED	2023-05-09	NCT05107739
Turnstone Biologics, Corp.	TBio-6517	—	TERMINATED	2023-01-23	NCT04301011
Rubius Therapeutics	RTX-321	—	TERMINATED	2022-11-30	NCT04672980
Repertoire Immune Medicines	RPTR-168	—	TERMINATED	2022-09-14	NCT04762225
Eli Lilly	LY3435151	—	TERMINATED	2020-03-05	NCT04099277
Rondo Therapeutics	RNDO-564	—	ENROLLING BY INVITATION	2029-02-28	NCT07218003
Instil Bio	ITIL-168	—	WITHDRAWN	2022-12-08	NCT05393635

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Cervical Cancer

VEGF (17) PD-1 (11)

Novel Drugs by Company (New molecular entities)

SEAGEN 1 drug

TIVDAK

TISOTUMAB VEDOTIN-TFTV

CELLTRION 1 drug

Merck 1 drug

Reformulations (6 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

BIO-THERA SOLUTIONS LTD